Skip to main content

CombiMatrix, University of Washington to Co-develop Array-Based Dx for Lymphoma

NEW YORK, Sept. 11 (GenomeWeb News) - CombiMatrix and the Universityof Washingtonplan to co-develop a microarray-based test for diagnosing lymphoma, the two groups said today.

A team of university researchers led by Daniel Sabath and Stephen Schmechel, at the Departments of Laboratory Medicine and Pathology in the Schoolof Medicine, claimed to have identified a subset of genes whose expression pattern can "distinguish the various lymphoma types." The goal of the collaboration, then, is to harness those data and develop array-based diagnostics that detect lymphomas and predict clinical outcome.

To help develop and commercialize a potential product, CombiMatrix has penned an agreement with RationalDiagnostics. Last year, Seattle-based RationalDiagnostics, which was co-founded by Sabath and Schmechel, signed a deal with the Universityof Washingtonand the WashingtonTechnologyCenterthat ultimately helped uncover ways of using microarrays to diagnose lymphoma.

 

Existing methods of diagnosing lymphoma, which are based on examining tissue biopsies for a small number of markers, are often inaccurate and offer physicians "limited information" about the expected course of a patient's cancer progression.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.